Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells

Qingbin Cui 1,2,*, Chao-Yun Cai 2, Jing-Quan Wang 2, Shuang Zhang 1, Pranav Gupta 2, Ning Ji 2, Yuqi Yang 2, Xingduo Dong 2, Dong-Hua Yang 2 and Zhe-Sheng Chen 2,*

1 School of Public Health, Guangzhou Medical University, Guangzhou 511436, China
2 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA
*Correspondence: chenz@stjohns.edu; Tel.: +1-718-990-1432; Fax: +1-718-990-1877

Received: 5 August 2019; Accepted: 21 August 2019; Published: 22 August 2019

Abstract: P-glycoprotein (P-gp), which is encoded by the ATP-binding cassette (ABC) transporter subfamily B member 1 (ABCB1) gene, is one of the most pivotal ABC transporters that transport its substrates across the cell membrane. Its overexpression is one of the confirmed causes of multidrug resistance (MDR), which results in the failure of cancer treatment. Here, we report that checkpoint kinase (Chk) 1 inhibitor MK-8776, a drug candidate in clinical trial, can restore the sensitivity of chemotherapeutics that are substrates of P-gp in KB-C2, SW620/Ad300 cells and human embryonic kidney (HEK)293/ABCB1 cells that overexpress P-gp. MK-8776 remarkably enhanced the cellular [3H]-paclitaxel accumulation and suppressed the efflux function of P-gp without reducing its expression and affecting its cellular localization in cancer cells. Furthermore, MK-8776 (0–40 µM) stimulated the activity of ATPase in P-gp, which was 4.1-fold greater than the control. In addition, MK-8776 formed a cation–π bond and π–π interaction with key residues of the substrate-binding site in P-gp, as indicated by computer-aided molecular docking study. Our study indicated that MK-8776 may significantly enhance the sensitivity of chemotherapeutics that are substrates of P-gp, providing important information for its application in the reversal of MDR.

Keywords: P-gp; multidrug resistance; MK-8776; restore; sensitivity

1. Introduction

ATP-binding cassette (ABC) transporters present in the cell membrane are a group of ATP-dependent pumps that transport their substrates in and/or out of cells [1,2]. The substrates include endogenous inorganic anions, certain metal ions, amino acids and their formed peptides and sugars, as well as various hydrophobic compounds, exogenous chemicals, drugs and their cellular metabolites [2,3]. P-glycoprotein (P-gp), also named multidrug resistance 1 (MDR1), is encoded by the ABC subfamily B member 1 (ABCB1) gene. It is one of the most critical ABC transporters that localize in the cell membrane of various organs and the blood–brain barrier. Generally, P-gp mediates the resistance of cytotoxic and targeted chemotherapeutics by transporting them out of cancer cells without chemical modification [4]. Previous studies have found that P-gp is overexpressed in resistant breast cancer, lung cancer and colon cancer cells [5–7], as well as in patients with neuroblastoma, acute myeloid leukemia, acute lymphoblastic leukemia [8–11] and many other cancers [12], indicating that it is an important target, the inhibitor of which is emerging as one promising approach to overcome MDR [13,14]. However, the development of such small molecules has been unsuccessful, mainly due to unexpected severe adverse effects and/or low efficacy in improving the therapeutic outcomes as measured in clinical trials [15,16].
Recently, novel molecules such as natural products and many tyrosine kinases inhibitors (TKIs) are found to be P-gp modulators [17,18]. The combination of certain TKIs at non-toxic concentration with chemotherapeutics can reverse MDR via the suppression of the expression or inhibition of the efflux function of P-gp [13,19]. Checkpoint kinases (Chk), composed of two subtypes, Chk1 and Chk2, are mediators that play crucial roles in regulating DNA damage and the cell cycle by phosphorylating their substrate proteins, leading to the activation of DNA damage checkpoints, DNA repair, cell cycle transition, and apoptosis inhibition [20,21]. Activated by the single-stranded DNA or double-strand breaks (DSBs) of DNA, Chks, which are phosphorylated by ataxia telangiectasia mutated (ATM) and Rad3 related kinase (ATR), can promote the G2/M-phase and intra-S-checkpoints (Chk1), or evoke the p53-associated G1/S-phase checkpoint and S-phase cell cycle arrest (Chk2) [22], which in turn provide the time for DNA repair before allowing the cells with damaged DNA to perform mitosis [23]. MK-8776 (Figure 1A) is a Chk1 inhibitor in clinical trials for certain advanced solid tumors and acute myeloid leukemia [24,25]. MK-8776 works synergistically with radiotherapy and certain chemotherapy to combat human non-small lung cancer (NSCLC), leukemia and triple negative breast cancer via DSB repair inhibition, cell cycle arrest and autophagy inhibition [26–28]. In this work, we report that MK-8876 may restore the sensitivity of chemotherapeutics that are P-gp substrates to cancer cells that overexpress P-gp, suggesting its potential in circumventing P-gp-mediated MDR in cancer.

2. Results

2.1. MK-8776 Restored the Sensitivity of Chemotherapeutics in P-gp-Overexpressing Cancer Cells

We first determined the non-toxic concentration of MK-8776 tested for its resensitizing effects by the 3-(4,5-dimethylthiazol-yl)-2,5-di phenyltetrazolium bromide (MTT) assay. As shown in Figure 1B–D, in KB-3-1, SW620, HEK293 and their corresponding drug-resistant KB-C2, SW620/Ad300, HEK293/ABCB1 cells that overexpressed P-gp, the IC50 values of MK-8776 towards these cells ranged from 2–6 μM. Non-toxic concentration was at around 1 μM, so 0.3 and 1 μM were adopted for the re-sensitizing study.

Figure 1. The chemical structure of MK-8776 (A), and the cell viability curve of human epidermoid carcinoma cell line KB-3-1 and its drug resistant KB-C2 cells (B), colon cancer cell line SW620 and doxorubicin-resistant SW620/Ad300 cells (C) that overexpress P-gp, HEK293/pcDNA3.1 and ABCB1 transfected HEK293/ABCB1 cells (D) upon treatment with MK-8776.

Next, we tested the cytototoxicity of P-gp substrates, including doxorubicin, paclitaxel and colchicine, with or without co-administration of MK-8776. In this experiment, the positive control, verapamil
(3 μM), a non-selective P-gp inhibitor, and negative control, cisplatin, a non-substrate of P-gp, were also measured.

As shown in Tables 1 and 2, doxorubicin, paclitaxel and colchicine exhibited much higher sensitivity towards KB-3-1, HEK293 and SW620 cells than KB-C2, HEK293/ABCBI and SW620/Ad300 cells that overexpress P-gp. The resistance fold (RF, IC50 values of substrates in the resistant cell lines in the presence or absence of MK-8776 or verapamil divided the IC50 values of substrates in the parental cells without MK-8776 or verapamil) ranged from 97.88 to 695.75. The overexpression of P-gp indeed caused resistance properties for its substrates, as confirmed in HEK293/ABCBI cells (RF 10.34–51.46).

**Table 1.** MK-8776-sensitized doxorubicin, paclitaxel, and colchicine in KB-C2 and HEK293/ABCBI cells.

| Compounds                  | IC50 ± SD (μM) (RF) |
|----------------------------|---------------------|
|                            | KB-3-1              | KB-C2               | HEK293/pcDNA3.1 | HEK293/ABCBI |
| Doxorubicin                | 0.017 ± 0.011 (1.00) | 1.664 ± 0.064 (97.88) | 0.061 ± 0.020 (1.00) | 0.631 ± 0.150 (10.34) |
| + MK-8776 (0.3 μM)         | 0.015 ± 0.003 (0.88) | 0.470 ± 0.041 (27.64) | 0.067 ± 0.017 (1.10) | 0.181 ± 0.014 (2.97) *|
| + MK-8776 (1 μM)           | 0.014 ± 0.004 (0.82) | 0.013 ± 0.004 (0.76) | 0.058 ± 0.027 (0.95) | 0.056 ± 0.033 (0.92) *|
| + Verapamil (3 μM)         | 0.014 ± 0.006 (0.52) | 0.016 ± 0.005 (0.94) | 0.061 ± 0.008 (1.00) | 0.084 ± 0.009 (1.38) *|
| Paclitaxel                 | 0.004 ± 0.002 (1.00) | 0.007 ± 0.007 (0.9) | 0.008 ± 0.006 (0.9) | 0.009 ± 0.009 (1.9) |
| + MK-8776 (0.3 μM)         | 0.004 ± 0.001 (1.00) | 0.144 ± 0.013 (36.00) | 0.122 ± 0.050 (1.67) | 0.259 ± 0.084 (3.49) *|
| + MK-8776 (1 μM)           | 0.003 ± 0.001 (0.75) | 0.002 ± 0.002 (23.00) | 0.100 ± 0.020 (1.37) | 0.047 ± 0.004 (0.64) *|
| + Verapamil (3 μM)         | 0.003 ± 0.001 (0.75) | 0.007 ± 0.002 (4.25) | 0.068 ± 0.003 (0.95) | 0.094 ± 0.003 (1.9) *|
| Colchicine                 | 0.012 ± 0.004 (1.00) | 0.006 ± 0.001 (1.00) | 1.538 ± 0.090 (25.30) |
| + MK-8776 (0.3 μM)         | 0.009 ± 0.005 (0.75) | 0.292 ± 0.203 (24.33) | 0.058 ± 0.007 (0.88) | 0.126 ± 0.106 (1.91) *|
| + MK-8776 (1 μM)           | 0.009 ± 0.003 (0.75) | 0.009 ± 0.030 (0.75) | 0.048 ± 0.009 (0.73) | 0.047 ± 0.021 (0.71) *|
| + Verapamil (3 μM)         | 0.008 ± 0.003 (0.66) | 0.006 ± 0.005 (0.5) | 0.056 ± 0.006 (0.65) | 0.050 ± 0.008 (0.76) *|
| Cisplatin                  | 2.598 ± 0.432 (1.00) | 3.027 ± 0.334 (1.21) | 2.660 ± 0.430 (1.00) | 3.336 ± 0.900 (1.25) |
| + MK-8776 (0.3 μM)         | 2.440 ± 0.264 (0.97) | 2.770 ± 0.167 (1.10) | 2.378 ± 0.136 (0.89) | 2.727 ± 0.592 (1.03) |
| + MK-8776 (1 μM)           | 2.431 ± 0.179 (0.97) | 2.652 ± 0.087 (1.05) | 2.474 ± 0.286 (0.93) | 2.611 ± 0.353 (0.98) |
| + Verapamil (3 μM)         | 2.309 ± 0.642 (0.97) | 2.098 ± 0.230 (0.84) | 2.388 ± 0.452 (0.90) | 3.115 ± 0.433 (1.17) |

* p < 0.05 vs. control. * Three independent experiments which were performed in triplicate.  

**Table 2.** MK-8776-sensitized doxorubicin and paclitaxel in SW620/Ad300 cells.

| Compounds                  | IC50 ± SD (μM) (RF) |
|----------------------------|---------------------|
|                            | SW620               | SW620/Ad300         |
| Doxorubicin                | 0.031 ± 0.014 (1.00) | 9.950 ± 2.023 (320.97) |
| + MK-8776 (0.3 μM)         | 0.028 ± 0.016 (0.90) | 1.362 ± 0.122 (43.94) *|
| + MK-8776 (1 μM)           | 0.035 ± 0.012 (1.13) | 0.426 ± 0.184 (13.74) *|
| + Verapamil (3 μM)         | 0.038 ± 0.021 (1.23) | 0.096 ± 0.023 (3.10) *|
| Paclitaxel                 | 0.091 ± 0.015 (1.00) | 21.19 ± 6.25 (232.86) |
| + MK-8776 (0.3 μM)         | 0.076 ± 0.038 (0.84) | 1.784 ± 0.125 (19.60) *|
| + MK-8776 (1 μM)           | 0.074 ± 0.003 (0.81) | 0.597 ± 0.566 (6.56) *|
| + Verapamil (3 μM)         | 0.113 ± 0.006 (1.24) | 0.639 ± 0.023 (7.03) *|
| Cisplatin                  | 1.481 ± 0.676 (1.00) | 1.514 ± 0.398 (1.02) |
| + MK-8776 (0.3 μM)         | 1.329 ± 0.156 (0.90) | 1.423 ± 0.438 (0.94) |
| + MK-8776 (1 μM)           | 1.228 ± 0.181 (0.83) | 1.266 ± 0.295 (0.84) |
| + Verapamil (3 μM)         | 1.164 ± 0.107 (0.79) | 1.851 ± 0.364 (1.25) |

* p < 0.05 vs. control. * Three independent experiments which were performed in triplicate.  

Importantly, when co-administrated with MK-8776, these chemotherapeutics demonstrated significantly lower IC50 values to KB-C2 and SW620/Ad300 cells compared with that in the absence of MK-8776. Similarly, MK-8776 restored the sensitivity of all the three chemotherapeutics to P-gp-transfected HEK293/ABCBI cells. In addition, the co-administration of MK-8776 showed no impact to KB-3-1, SW620, and HEK293 cells and no impacts on cisplatin in all the cell lines.
2.2. **MK-8776 Increased P-gp Substrate [3H]-Paclitaxel Accumulation and Suppressed its Efflux in KB-C2 Cells**

The efflux mediated by P-gp may severely restrain the intracellular accumulation of certain chemotherapeutics, leading to drug resistance [13]. As MK-8776 restored the sensitivity of P-gp substrates, we further measured its effects on P-gp efflux function by evaluating the intracellular accumulation and extracellular concentration of radioactive [3H]-paclitaxel at different times. The P-gp-overexpressing KB-C2 cells were treated with or without MK-8776 (0.3, 1 μM) for 2 h, and then the intracellular concentration of [3H]-paclitaxel was measured by Packard TRI-CARB 1900CA liquid scintillation analyzer. Moreover, the extracellularity of [3H]-paclitaxel was also measured.

As shown in Figure 2, in KB-C-2 cells, the [3H]-paclitaxel concentration decreased significantly and [3H]-paclitaxel efflux increased significantly compared with that in their parental KB-3-1 cells. Pretreatment with MK-8776 significantly increased the accumulation and inhibited the efflux of [3H]-paclitaxel in KB-C2 cells, while MK-87776 showed no such effects on KB-3-1 cells. These results indicated that MK-8776 may impact the efflux function of P-gp.

![Figure 2](image-url)

**Figure 2.** Effects of MK-8776 on the intracellular accumulation of [3H]-paclitaxel in KB-C2 cells that overexpress P-gp (A,C) and their parent KB-3-1 cells (A,B). *p < 0.05 vs. control.

2.3. **MK-8776 Did Not Alter the Expression of P-gp in KB-C2 Cells**

We then tested the expression of P-gp on MK-8776 in KB-C2 cells. Cells were treated with MK-8776 with different times (1 μM for 0, 24, 48, 72 h) and doses (0.1, 0.3, 1 μM for 72 h). Then, the P-gp expression in different groups was measured by Western blot assay. KB-3-1 cells were used as a negative control.

The results in Figure 3 show that KB-3-1 cells expressed no P-gp, but KB-C2 cells expressed high P-gp, which could lead to the MDR property. However, P-gp expression was not significantly altered by MK-8776. The above two results indicated the MK-8776 might suppress the efflux function without altering the cellular expression of P-gp.
altered by MK-8776. The above two results indicated the MK-8776 might suppress the efflux function without altering the cellular expression of P-gp.

Figure 3. Effects of MK-8776 on P-gp expression in KB-C2 cells. *p < 0.05 vs. control. NS, not significant.

2.4. MK-8776 Did Not Alter P-gp Subcellular Localization

Since MK-8776 did not alter the P-gp expression in cells, we next tested the cellular localization of P-gp by immunofluorescence assay. SW620/Ad300 cells were treated with 1 µM of MK-8776 for 0, 24, 48, 72 h, and then P-gp was labeled by Alexa Fluor 488 dye. In this experiment, SW620 cells were used as a negative control, and DAPI was used to counterstain the nuclei.

The results in Figure 4 indicate that P-gp accumulated mostly in the membrane of cancer cells, while the MK-8776 treatment did not alter the cellular localization of P-gp significantly.

Figure 4. Effects of MK-8776 on the cellular localization of P-gp in P-gp-overexpressing SW620/Ad300 cells. Pictures were taken under 10× magnification microscope. Green: P-gp. Blue: nuclei.

2.5. MK-8776 Stimulated ATPase Activity

To obtain more details of the action mode of MK-8776 on P-gp, we determined the ATPase upon MK-8776 (0–40 µM) by measuring the P-gp-mediated ATP hydrolysis. The result in Figure 5 shows that stimulated ATPase activity of P-gp in a dose-dependent manner was observed upon MK-8776. MK-8776 exerted a concentration of 50% stimulation at 3.8 µM and exhibited 4.1-fold greater stimulation than that of the control.
2.6. Induced-Fit Docking (IFD) Simulation Interactions between P-gp and MK-8776

We performed the IFD to evaluate the interaction between MK-8776 and P-gp by molecular docking analysis. Our results showed that the docking score of MK-8776 to P-gp was −7.535 kcal/mol, indicating a good affinity. Figure 6 showed that there was one cation–π bond between the ionized amine of MK-8776 and the Tyr310 of human P-gp. The imidazopyrimidine group of MK-8776 formed a π–π interaction with Phe983 of residues of P-gp in the drug-binding site.

![Figure 6. Docking study of MK-8776 with human P-gp. (A) The generated 2D figure of the docked position of MK-8776 within the P-gp crystal. The polar residues are indicated with cyan bubbles, and the hydrophobic residues are indicated with green bubbles. Furthermore, the cation–π bond in the figure is shown as red arrow, and the π–π interaction is shown as green line. (B) The enlarged 3D figure of the docked position of MK-8776 within the drug-binding site of human P-gp. The structure of MK-8776 is shown as a ball and stick mode with the atoms colored as follows: carbon with cyan, nitrogen with blue, bromine with dark red. The important residues of P-gp are shown as sticks, with the atoms colored as follows: carbon with grey, nitrogen with blue, oxygen with red, hydrogen with white. The cation–π bond is indicated with green dotted line. The π–π stacking interactions are indicated with a blue dotted line.](image)

3. Discussion

MDR, which is one of the leading causes of treatment failure in cancer, refers to a phenomenon whereby, after a short time of chemotherapeutic treatment, cancer cells become resistant to other
chemotherapeutics with different mechanisms [29]. A very limited number of drugs are available for patients with late-term cancer or recurrent cancer, which become resistant to multiple therapeutic modalities. Various mechanisms may lead to MDR, such as the increase of drug efflux, the activation of cell signaling, growth, migration and other defense systems, the inhibition of apoptosis, and activation of DNA repair [30–33]. Among all these mechanisms, the overexpression of the ABC transporters which regulate the uptake and efflux of chemotherapeutics [15,16], especially P-gp, is one of the recognized pathways that confers MDR to small molecule-based therapy [34,35]. Beside the development of special P-gp regulators, drug repurposing has emerged as another appealing strategy as those molecules have been assessed in clinical/preclinical trials and considered as safe enough [36,37]. Many small molecular drugs, including TKIs [38], phosphodiesterase inhibitors [39], and fluoroquinolone antibiotics [40], antagonize P-gp mediated MDR at non-cytotoxic concentrations. These studies provide important information for future clinical trials and for further new drugs targeting P-gp.

MK-8776 is a Chk1 inhibitor that is under clinical trials for acute leukemia and certain advanced solid tumors. In a phase-I clinical trial, MK-8776 was shown to be well tolerated by single or combination use, accompanied with positive outcomes of clinical efficacy [25]. The results of phase II are yet to be announced. A previous study found that, beside the mechanism of Chk-related DNA repair and cell cycle suppression that can sensitize radiotherapy, or gemcitabine, which induces DNA DSBs [27,28], MK-8776 could also exert its re-sensitizing effects to different therapies via autophagy inhibition [26].

In this current work, we found that MK-8776 could restore the sensitivity of chemotherapeutics which are P-gp substrates to P-gp-overexpressing cancer cells by regulating the efflux function. The chemotherapeutics that are P-gp substrates exhibited resistance profiles (up to more than 600-fold) to KB-C2 and SW620/Ad300 cells but not to KB-3-1 and SW620 cells which expressed no P-gp. The combination of MK-8776 at 0.3 and 1 µM (non-toxic concentration) remarkably lower the IC50 values of KB-C2 and SW620/Ad300 cells, suggesting its re-sensitizing effects. MK-8776 exhibited similar effects to these three drugs in HEK293/ABCB1 cells, which are normal cell lines that were transfected with ABCB1; meanwhile, it exhibited no such effects to the non-Pgp substrate cisplatin, indicating its effects in modulating P-gp functions. As we can observe, since all cells expressed a high level of P-gp [40], the RF of the chemotherapeutics and the reversal effects by MK-8776 in KB-C2 or SW620/Ad300 cells and HEK293/ABCB1 cells were different. The RF in KB-C2 or SW620/Ad300 cells were higher than in HEK293/ABCB1 cells, and the reversal effects of MK-8776 and verapamil in KB-C2 or SW620/Ad300 cells were weaker than in HEK293/ABCB1 cells. This is probably due to the other resistant factors (except the overexpression of P-gp) of different chemotherapeutics on different cancer cells, and/or different levels of P-gp, suggesting that higher transporter expression levels may require a higher inhibitor concentration to achieve a certain inhibitory effect [41,42].

To explore the mechanism, we further conducted the Western blot and immunofluorescence study to test the effects of MK-8776 to the expression and cellular localizations of P-gp. The results indicated that MK-8776 did not alter either of them, while it could stimulate the ATPase of P-gp, an effect that was similar to the P-gp inhibitor verapamil [43]. This effect of stimulating ATPase may competitively limit the uptake of substrate of P-gp, which can lead to the inhibition efflux function. Indeed, MK-8776 significantly suppressed the efflux of [3H]-paclitaxel, resulting in more accumulation of [3H]-paclitaxel in KB-C2 cells. In addition, the molecular modeling indicated that MK-8776 could form a cation–π bond and π–π interaction with the drug-binding pocket of human P-gp, which may lead to the inhibition of efflux. Our work provided useful information regarding the potential application of MK-8776 in the treatment of resistant cancer that overexpresses P-gp.

Although the discovery of P-gp inhibitors so far seems not to have been successful, the full functions of P-gp in drug transport and diseases progression need to be revealed [15]. The findings of our group appear to suggest that rather than being tyrosine kinase-related (although this could not be excluded), those agents that show ABC transporter-regulating effects are probably structure-related, suggesting that certain structures may tend to regulate the efflux functions of ABC transporters. Their further application in clinical practice could be achieved after their safety/pharmacokinetics
profiles are combined with chemotherapeutics, and the exact mechanism and binding sites have been fully deciphered.

4. Materials and Methods

4.1. Chemicals and Reagents

Chk1 inhibitor MK-8776 was a kind gift from ChemieTek (Indianapolis, IN, USA). Dulbecco’s modified Eagle’s Medium (DMEM), fetal bovine serum (FBS), bovine serum albumin (BSA), antibacterial penicillin/streptomycin solution (100×), trypsin (0.25%) were purchased from Hyclone (GE Healthcare Life Science, Pittsburgh, PA, USA). Monoclonal antibodies, P-gp (C219) and Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH, MA5-15738), and secondary antibody Alexa Fluor 488 conjugated goat anti-mouse IgG used in immunofluorescence assay were purchased from Thermo Fisher Scientific Inc (Rockford, IL, USA), Triton X-100, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), propidium iodide (PI), 36% paraformaldehyde, chemotherapeutics paclitaxel, doxorubicin, colchicine, cisplatin and verapamil were purchased from Sigma-Aldrich (St. Louis, MO, USA). Radioactive [3H]-paclitaxel (15 Ci/mmol) was purchased from Moravek Biochemicals, Inc (Brea, CA, USA). The chemical materials for the ATPase assay were the same as those in our previous work [14,19].

4.2. Cell Lines and Cell Culture

Human epidermoid carcinoma KB-3-1 cells and their colchicine-selected KB-C2 cells that overexpress P-gp, colon cancer cells SW620 and doxorubicin-resistant SW620/Ad300 cells that overexpress P-gp [44], human embryonic kidney 293 (HEK293) cells transfected with the empty pcDNA3.1 vector, HEK293/pcDNA3.1 cells, and HEK293 cells transfected with the vector containing a full length of ABCB1 and HEK293/ABCB1 cells were used for the chemotherapeutic re-sensitizing study. HEK293/pcDNA3.1 and HEK293/ABCB1 cells were cultured in a medium containing 2 mg/mL of G418 for two weeks before re-sensitizing assay. SW620 and SW620/Ad300 cells were used for the immunofluorescence analysis. All cells were cultured in DMEM that contained 10% FBS and 1% antibacterial at 37 °C, 5% CO₂. All the drug-resistant cell lines were allowed to grow as an adherent monolayer in a drug-free culture media for more than 2 weeks before the study.

4.3. Cytotoxicity experiments

The cytotoxicity and re-sensitizing experiments of MK-8776 to KB-3-1, KB-C2, SW620, SW620/Ad300, HEK293/pcDNA3.1, HEK293/ABCB1 cells were determined by the MTT colorimetric assay as previously reported [45]. MK-8776 at 0.3 µM and 1 µM were applied based on the results of cytotoxicity experiments at non-cytotoxic concentrations. All experiments were repeated at least three times in triplicate, and the mean and standard deviation (SD) values were calculated by GraphPad Prism 7.00 software (GraphPad Software Inc., La Jolla, San Jose, CA, USA). The non-selective P-gp inhibitor verapamil (3 µM) was used as the positive control. Non-P-gp substrate cisplatin was used as the negative control drug.

4.4. Western Blot Analysis

The P-gp expression of KB-C2 cells upon MK-8776 (both dose-dependent—0, 0.1, 0.3, 1 µM—and time-dependent—0, 24, 48, 72 h) were determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Generally, equal amounts of cell lysates (30 µg protein) were resolved by SDS-PAGE and electrophoretically transferred onto polyvinylidene fluoride membranes. The presence of P-gp was confirmed using monoclonal P-gp antibody C219 (dilution 1:1000 in 5% milk in PBS). GAPDH (dilution 1:1000 in 5% milk in PBS) was used as a load control. The band quantification was conducted by Image J software (NIH, MD, USA). The detailed protocol was carried out according to our previous work [46].
4.5. Immunofluorescence Analysis

Immunofluorescence analysis was applied to study the impact of MK-8776 to the distribution of P-gp. SW620 and SW620/Ad300 cells were seeded in 24-well plates (1 × 10^4/well) and cultured for 24 h, followed by incubation with 1 µM MK-8776 for 0, 24, 48 and 72 h, respectively. Then, after being washed with PBS (3 times), the cells were fixed (4% paraformaldehyde, 5 min) and permeabilized (0.1% Triton X-100 in PBS, 5 min) before being blocked with 6% BSA for 1 h at 37 °C. The presence of P-gp was confirmed by monoclonal ABCB1 antibody C219 (dilution 1:1000 in 6% BSA in PBS) for incubation at 4 °C overnight. Secondary antibody Alexa Fluor 488 (dilution 1:1000 in 6% BSA in PBS) was used for incubation at 37 °C for 1 h. After washing with cold PBS (3 times), DAPI (1 µg/mL in PBS) was used to counterstain the nuclei. Immunofluorescence images were collected using an EVOS FL Auto fluorescence microscope (Life Technologies Corporation, Gaithersburg, MD, USA).

4.6. ATPase Assay

The ATPase activity of P-gp upon MK-8776 (0–40 µM) was tested by the PREDEASY ATPase Kits (TEBU-BIO nv, Boechout, Belgium) according to manufacturer’s instructions [46].

4.7. [3H]-Paclitaxel Accumulation and Efflux Assay

P-gp substrate and radioactive [3H]-paclitaxel was applied to measure the accumulation and the efflux effects of P-gp upon MK-8776 (0.3, 1 µM) by examining its intracellular and extracellular concentrations at different time. The non-selective P-gp inhibitor verapamil (3 µM) was used as the positive control [47].

4.8. Molecular Modeling of Human ABCB1 Homology Model

We conducted a computer-aided molecular docking study to predict the binding details of MK-8776 to P-gp. The docking experiments were performed according to the reported protocols [19,48] with Schrodinger 2018-1 software (Schrodinger, Cambridge, MA, USA). The ligand was essentially prepared by the default condition. Human ABCB1 (PDB: 6QEX) protein was prepared [49] and the docking grid was generated. Glide XP docking was conducted and the induced-fit docking (IFD) was performed after the receptor grid was generated by selecting residues in the substrate-binding site of P-gp.

4.9. Statistical Analysis

IC50 values and protein quantities were exhibited as the mean ± SD. All experiments were repeated at least three times, and the data were analyzed by a one-way or two-way ANOVA by GraphPad Prism 7.00 software. p < 0.05 was considered as significantly different.

5. Conclusions

The Chk inhibitor MK-8776 restored the sensitivity of chemotherapeutics that were P-gp substrates to P-gp-overexpressing cancer cell by suppressing the efflux.

Author Contributions: Conceptualization, Q.C., D.-H.Y., and Z.-S.C.; methodology, Z.-S.C., D.-H.Y., and Q.C; formal analysis, Q.C., C.-Y.C., J.-Q.W, P.G., N.J., S.Z., X.D., and Z.-S.C; data curation, Q.C., YY; writing—original draft preparation, Q.C.; writing—review and editing, Q.C., D.-H.Y., Z.-S.C.; supervision, Z.-S.C; project administration, Z.-S.C; funding acquisition, Z.-S.C.

Funding: This research was funded by National Natural Science Foundation of China (No. 81872901).

Acknowledgments: We thank Stephen Aller (The University of Alabama at Birmingham, Birmingham, AL) for providing the human ABCB1 homology model. We thank Tanaji T. Talele (St. John’s University) for providing the computing resources for the docking study. We thank Susan E. Bates and Robert W. Robey (NCI, NIH, Bethesda, MD) for providing the cell lines.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Vasiliou, V.; Vasiliou, K.; Nebert, D.W. Human ATP-binding cassette (ABC) transporter family. *Hum. Genom.* 2009, 3, 281–290. [CrossRef] [PubMed]

2. Nigam, S.K. What do drug transporters really do? *Nat. Rev. Drug Discov.* 2015, 14, 29–44. [CrossRef] [PubMed]

3. Begic, R.R.; Falasca, M. ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance. *Int. J. Mol. Sci.* 2017, 18, 2362. [CrossRef] [PubMed]

4. Fletcher, J.L.; Williams, R.T.; Henderson, M.J.; Norris, M.D.; Haber, M. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. *Drug Resist. Updat.* 2016, 26, 1–9. [CrossRef] [PubMed]

5. Hanke, N.T.; Imler, E.; Marron, M.T.; Seligmann, B.E.; Garland, L.L.; Baker, A.F. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines. *J. Cancer Res. Clin. Oncol.* 2018, 144, 1317–1327. [CrossRef] [PubMed]

6. Deshmukh, R.R.; Kim, S.; Elghoul, Y.; Dou, Q.P. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors. *J. Cell. Biochem.* 2017, 118, 1239–1248. [CrossRef] [PubMed]

7. Liu, Z.; Duan, Z.J.; Chang, J.Y.; Zhang, Z.F.; Chu, R.; Li, Y.L.; Dai, K.H.; Mo, G.Q.; Chang, Q.Y. Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression. *PLoS ONE* 2014, 9, e98560. [CrossRef] [PubMed]

8. Chan, H.S.; Haddad, G.; Thorner, P.S.; DeBoer, G.; Lin, Y.P.; Ondrusek, N.; Yeger, H.; Ling, V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. *N. Engl. J. Med.* 1991, 325, 1608–1614. [CrossRef] [PubMed]

9. de Figueiredo-Pontes, L.L.; Pintao, M.C.; Oliveira, L.C.; Dalmazzo, L.F.; Jacomo, R.H.; Garcia, A.B.; Falcao, R.P.; Rego, E.M. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. *Cytometry B Clin. Cytom.* 2008, 74, 163–168. [CrossRef] [PubMed]

10. Leith, C.P.; Kopecky, K.J.; Chen, I.M.; Eijdems, L.; Slovak, M.L.; McConnell, T.S.; Head, D.R.; Weick, J.; Grever, M.R.; Appelbaum, F.R.; et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. *Blood* 1999, 94, 1086–1099.

11. Kourtis, M.; Vavatsi, N.; Gombakis, N.; Sidi, V.; Tzimagiorgis, G.; Papageorgiou, T.; Koliouskas, D.; Athanassiadou, F. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia. *Int. J. Hematol.* 2007, 86, 166–173. [CrossRef] [PubMed]

12. Goldstein, L.J.; Galski, H.; Fojo, A.; Willingham, M.; Lai, S.L.; Gazdar, A.; Pirker, R.; Green, A.; Crist, W.; Brodeur, G.M.; et al. Expression of a multidrug resistance gene in human cancers. *J. Natl. Cancer Inst.* 1989, 81, 116–124. [CrossRef] [PubMed]

13. Kathawala, R.J.; Gupta, P.; Ashby, C.J.; Chen, Z.S. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. *Drug Resist. Updat.* 2015, 18, 1–17. [CrossRef] [PubMed]

14. Cui, Q.; Cai, C.Y.; Gao, H.L.; Ren, L.; Ji, N.; Gupta, P.; Yang, Y.; Shukla, S.; Ambudkar, S.V.; Yang, D.H.; et al. Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells. *Front. Oncol.* 2019, 9, 313. [CrossRef] [PubMed]

15. Robey, R.W.; Pluchino, K.M.; Hall, M.D.; Fojo, A.T.; Bates, S.E.; Gottesman, M.M. Revisiting the role of ABC transporters in multidrug-resistant cancer. *Nat. Rev. Cancer* 2018, 18, 452–464. [CrossRef] [PubMed]

16. Li, W.; Zhang, H.; Assaraf, Y.G.; Zhao, K.; Xu, X.; Xie, J.; Yang, D.H.; Chen, Z.S. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. *Drug Resist. Updat.* 2016, 27, 14–29. [CrossRef] [PubMed]

17. Wu, C.P.; Ohnuma, S.; Ambudkar, S.V. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. *Curr. Pharm. Biotechnol.* 2011, 12, 609–620. [CrossRef]

18. Anreddy, N.; Gupta, P.; Kathawala, R.J.; Patel, A.; Wurpel, J.N.; Chen, Z.S. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. *Molecules* 2014, 19, 13848–13877. [CrossRef]

19. Fan, Y.F.; Zhang, W.; Zeng, L.; Lei, Z.N.; Cai, C.Y.; Gupta, P.; Yang, D.H.; Cui, Q.; Qin, Z.D.; Chen, Z.S.; et al. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. *Cancer Lett.* 2018, 421, 186–198. [CrossRef]
20. Patil, M.; Pabla, N.; Dong, Z. Checkpoint kinase 1 in DNA damage response cell cycle regulation. *Cell Mol. Life Sci.* 2013, 70, 4009–4021. [CrossRef]

21. Smits, V.A.; Gillespie, D.A. DNA damage control: Regulation and functions of checkpoint kinase 1. *FEBS J.* 2015, 282, 3681–3692. [CrossRef] [PubMed]

22. Qiu, Z.; Oleinick, N.L.; Zhang, J. ATR/CHK1 inhibitors and cancer therapy. *Radiother. Oncol.* 2018, 126, 450–464. [CrossRef] [PubMed]

23. Smith, J.; Tho, L.M.; Xu, N.; Gillespie, D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. *Adv. Cancer Res.* 2010, 108, 73–112. [PubMed]

24. Webster, J.A.; Tibes, R.; Morris, L.; Blackford, A.L.; Litzow, M.; Patnaik, M.; Rosner, G.L.; Gojo, I.; Kinders, R.; Wang, L.; et al. Randomized phase II trial of cytotoxic arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed or refractory acute myeloid leukemia. *Leuk. Res.* 2017, 61, 108–116. [CrossRef] [PubMed]

25. Daud, A.I.; Ashworth, M.T.; Strosberg, J.; Goldman, J.W.; Mendelson, D.; Springett, G.; Venook, A.P.; Qiu, Z.; Oleinick, N.L.; Zhang, J.; et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. *J. Clin. Oncol.* 2015, 33, 1060–1066. [CrossRef] [PubMed]

26. Zhou, Z.R.; Yang, Z.Z.; Wang, S.J.; Zhang, L.; Luo, J.R.; Feng, Y.; Yu, X.L.; Chen, X.X.; Guo, X.M. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy. *Acta Pharmacol. Sin.* 2017, 38, 513–523. [CrossRef] [PubMed]

27. Daud, A.I.; Ashworth, M.T.; Strosberg, J.; Goldman, J.W.; Mendelson, D.; Springett, G.; Venook, A.P.; Loehnert, S.; Rosen, L.S.; Shanahan, F.; et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. *J. Clin. Oncol.* 2015, 33, 1060–1066. [CrossRef] [PubMed]

28. Zhou, Z.R.; Yang, Z.Z.; Wang, S.J.; Zhang, L.; Luo, J.R.; Feng, Y.; Yu, X.L.; Chen, X.X.; Guo, X.M. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy. *Acta Pharmacol. Sin.* 2017, 38, 513–523. [CrossRef] [PubMed]

29. Dai, Y.; Chen, S.; Kmiecik, M.; Zhou, L.; Lin, H.; Pei, X.Y.; Grant, S. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. *Mol. Cancer Ther.* 2013, 12, 878–889. [CrossRef]

30. Bridges, K.A.; Chen, X.; Liu, H.; Rock, C.; Buchholz, T.A.; Shumway, S.D.; Skinner, H.D.; Meyn, R.E. MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. *Oncotarget* 2016, 7, 71660–71672. [CrossRef]

31. Zinzi, L.; Capparella, E.; Cantore, M.; Contino, M.; Leopoldo, M.; Colabufo, N.A. Small and Innovative Molecules as New Strategy to Revert MDR. *Front. Oncol.* 2014, 4, 2. [CrossRef]

32. Li, Y.J.; Lei, Y.H.; Yao, N.; Wang, C.R.; Hu, N.; Ye, W.C.; Zhang, D.M.; Chen, Z.S. Modulating ROS to overcome multidrug resistance in cancer. *Chin. J. Cancer* 2017, 36, 52. [CrossRef] [PubMed]

33. Taylor, S.; Spugnini, E.P.; Assaraf, Y.G.; Azzarito, T.; Rauch, C.; Fais, S. Microenvironment acidity as a major determinant of tumor chemo-resistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. *Drug Resist. Updat.* 2015, 23, 69–78. [CrossRef] [PubMed]

34. Baguley, B.C. Multiple drug resistance mechanisms in cancer. *Mol. Biotechnol.* 2010, 46, 308–316. [CrossRef] [PubMed]

35. Eadie, L.N.; Hughes, T.P.; White, D.L. ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. *PLoS ONE* 2016, 11, e161470. [CrossRef] [PubMed]

36. Agrawal, M.; Hanfstein, B.; Erben, P.; Wolf, D.; Ernst, T.; Fabarius, A.; Saussele, S.; Purkayastha, D.; Woodman, R.C.; Hofmann, W.K.; et al. MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure. *Leukemia* 2014, 28, 1478–1485. [CrossRef] [PubMed]

37. Regulska, K.; Regulski, M.; Karolak, B.; Murias, M.; Stanisz, B. Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing. *Drug Discov. Today* 2019, 24, 1059–1065. [CrossRef] [PubMed]

38. Pushpakom, S.; Iorio, F.; Eyers, P.A.; Escott, K.J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; et al. Drug repurposing: Progress, challenges and recommendations. *Nat. Rev. Drug Discov.* 2018, 17, 14. [CrossRef]

39. Beretta, G.L.; Cassinelli, G.; Pennati, M.; Zuco, V.; Gatti, L. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. *Eur. J. Med. Chem.* 2017, 142, 271–289. [CrossRef]

40. Chen, J.J.; Sun, Y.L.; Tiwari, A.K.; Xiao, Z.J.; Sodani, K.; Yang, D.H.; Vispute, S.G.; Jiang, W.Q.; Chen, S.D.; Chen, Z.S. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. *Cancer Sci.* 2012, 103, 1531–1537. [CrossRef]
40. Gupta, P.; Gao, H.L.; Ashar, Y.V.; Karadkhelkar, N.M.; Yoganathan, S.; Chen, Z.S. Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates. *Int. J. Mol. Sci.* 2019, 20, 268. [CrossRef]

41. Ruzickova, E.; Janska, R.; Dolezel, P.; Mlejnek, P. Clinically relevant interactions of anti-apoptotic Bcl-2 protein inhibitors with ABC transporters. *Pharmazie* 2017, 72, 751–758. [PubMed]

42. Mlejnek, P.; Kosztyu, P.; Dolezel, P.; Bates, S.E.; Ruzickova, E. Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. *Chem. Biol. Interact.* 2017, 273, 171–179. [CrossRef] [PubMed]

43. Sharom, F.J.; Yu, X.; Chu, J.W.; Doige, C.A. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. *Biochem. J.* 1995, 308(Pt. 2), 381–390. [CrossRef]

44. Lai, G.M.; Chen, Y.N.; Mickley, L.A.; Fojo, A.T.; Bates, S.E. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. *Int. J. Cancer* 1991, 49, 696–703. [CrossRef] [PubMed]

45. Shi, Z.; Tiwari, A.K.; Shukla, S.; Robey, R.W.; Singh, S.; Kim, I.W.; Bates, S.E.; Peng, X.; Abraham, I.; Ambudkar, S.V.; et al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. *Cancer Res.* 2011, 71, 3029–3041. [CrossRef] [PubMed]

46. Ji, N.; Yang, Y.; Lei, Z.N.; Cai, C.Y.; Wang, J.Q.; Gupta, P.; Xian, X.; Yang, D.H.; Kong, D.; Chen, Z.S. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. *Biochem. Pharmacol.* 2018, 158, 274–285. [CrossRef] [PubMed]

47. Ji, N.; Yang, Y.; Cai, C.Y.; Lei, Z.N.; Wang, J.Q.; Gupta, P.; Shukla, S.; Ambudkar, S.V.; Kong, D.; Chen, Z.S. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. *Cancer Lett.* 2019, 440, 82–93. [CrossRef] [PubMed]

48. Zhang, Y.K.; Zhang, G.N.; Wang, Y.; Patel, B.A.; Talele, T.T.; Yang, D.H.; Chen, Z.S. Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. *Sci. Rep.* 2016, 6, 25694. [CrossRef]

49. Alam, A.; Kowal, J.; Broude, E.; Roninson, I.; Locher, K.P. Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. *Science* 2019, 363, 753–756. [CrossRef]